| Overview |
| bs-44020P-APC-100ug |
| Recombinant SARS-Cov-2 N protein (EG.5/BA.4/BA.4.6)（P13L，DEL31-33，R203K，G204R，S413R）,N-His, APC Conjugated |
| Others |
| Others |
| Specifications |
| APC |
| Recombinant SARS-Cov-2 N protein (EG.5/BA.4/BA.4.6)（P13L，DEL31-33，R203K，G204R，S413R）is expressed in E.coli with N-His. It contains the amino acid sequence of 1-419/419 |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Target |
| P0DTC2 |
| The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct. |
Powered by Bioz